Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2529]

Misidentified and contaminated cell lines lead to faulty cancer science

Misidentified and contaminated cell lines lead to faulty cancer science

EHA 17: Malignant cells in patients with chronic lymphocytic leukaemia escape T cell recognition and attack

EHA 17: Malignant cells in patients with chronic lymphocytic leukaemia escape T cell recognition and attack

EHA 17: Evaluation of a single iron dose as ferric carboxymaltose (FCM) for fatigue treatment in iron deficient women

EHA 17: Evaluation of a single iron dose as ferric carboxymaltose (FCM) for fatigue treatment in iron deficient...

Mutations in KRAS lead to acquired resistance to anti-EGFR therapy in colorectal cancer

Mutations in KRAS lead to acquired resistance to anti-EGFR therapy in colorectal cancer

Poorest bowel cancer patients more likely to die within month of surgery

Poorest bowel cancer patients more likely to die within month of surgery

New drug is 'greatest advance' for basal cell skin cancer

New drug is 'greatest advance' for basal cell skin cancer

ASCO 2012: Duloxetine, a serotonin-norepinephrine reuptake inhibitor anti-depressant, is first effective treatment for chemotherapy-induced peripheral neuropathy

ASCO 2012: Duloxetine, a serotonin-norepinephrine reuptake inhibitor anti-depressant, is first effective treatment...

ASCO 2012: Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Newer, more costly drugs no better than standard weekly paclitaxel as first line therapy for locally advanced or metastatic breast cancer

ASCO 2012: Newer, more costly drugs no better than standard weekly paclitaxel as first line therapy for locally...

ASCO 2012: New BRAF inhibitor dabrafenib delays disease progression better than standard chemotherapy in patients with advanced melanoma

ASCO 2012: New BRAF inhibitor dabrafenib delays disease progression better than standard chemotherapy in patients...

More from ecancer